HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
about
Strategies to reduce hepatitis C virus recurrence after liver transplantationDiagnosis, management, and treatment of hepatitis C: an updateSevere adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.Future treatment of patients with HCV cirrhosis.Management of recurrent hepatitis C following liver transplantation.Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma.Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Treatment of patients with HCV related cirrhosis: many rewards with very few risks.IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patientsSASLT practice guidelines: management of hepatitis C virus infection.Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.Direct-acting antiviral agents in patients with hepatitis C cirrhosis.Hepatitis B and C in liver transplantation: new strategies to combat the enemies.Role of liver biopsy in the era of direct-acting antivirals.Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortalityEvaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico ApproachesHigh sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis.Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China.Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis.Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology.Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.
P2860
Q22305418-C1A7E094-C8C7-48C0-9668-989A1A19842DQ29619682-90404496-8C8B-4E04-8ABD-81D9E139CE99Q33406835-08CF4D83-85C9-4461-A3AC-304CEAB16259Q34243993-64C84ED5-6DC6-4765-AA2D-6B1B3E0D1C96Q34298333-83CC08F7-4CCC-437F-B308-B54C251985E5Q34334776-AE09FE3B-3EA1-4821-9B0E-C078D3D161D2Q34467312-02248F4E-BD8C-4865-8ED4-D28D34E16CE2Q34725891-A5B062B2-53CE-47EB-810F-40B1F64C410CQ35226081-128C8063-3099-4D77-A30D-5F1F2113BC76Q36142732-59A86DA3-DE48-4E7A-B5A0-952CD87D1499Q36935025-1DCA9656-0573-430E-968B-AC8E9E17F5A0Q36983527-A8DFA824-4EB0-4908-98BB-152DDA74CB51Q37019765-F6B73DBA-86E5-4E65-B14D-7DA65C2AF5B9Q37534731-0082C524-00C0-4AD4-9572-7633FE679FC6Q37663921-49F3133E-6DE4-428E-B27F-668D923DA67DQ38067343-C9AFAC6C-2D76-4ED4-9F37-A337BEAFD32BQ38074087-645E420A-402F-4F01-BB24-244537F780A1Q38198618-BADB8218-7C4F-49AD-AFD2-F86E9742C208Q40902793-F563939F-F206-4882-9F7E-0E25CD7E5D95Q41412067-48899E95-4A91-4674-80F7-740385F811ABQ42287249-F707D87A-F002-4C73-8598-433476492DF2Q42581407-DCD71160-6028-4246-A1DF-E6B1541F2663Q42987104-98D8E006-B791-4B0E-8758-0A247BA09A64Q43000439-65EE072F-A008-499A-A3F4-0C8049DC6A9CQ43736700-ABF0FB07-B597-446D-9616-497845F25BB5Q44074214-F5BAA3A0-6434-4C0A-82B2-9E7EF1FF7E1BQ45027152-819CE47E-A830-4154-83C0-0857F8F8576EQ45353010-9A41DB0B-0DDC-4DB3-91E8-E85AEE9BB1A2Q45836877-8BB6D616-CF77-4585-960F-C54772633408
P2860
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@en
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@nl
type
label
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@en
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@nl
prefLabel
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@en
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@nl
P2093
P2860
P1476
HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.
@en
P2093
Alicia Esteban
Andreas Cerny
Beat Helbling
Beat Meyer-Wyss
Beat Müllhaupt
Eberhard L Renner
Ivan Stamenic
J Borovicka
Jean-Jacques Gonvers
Marina Knöpfli
P2860
P304
P356
10.1111/J.1365-2893.2006.00753.X
P577
2006-11-01T00:00:00Z